GlassScriptPhysician profile
Sunnie S Kim
NPI 1770726465
$80,958.75
in general payments reported to CMS, 2019-2025
18 companies · $37K in 2025
The $37K reported for 2025 was more than what 93% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2021: $5,988 · 2022: $7,231 · 2023: $9,377 · 2024: $22K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Travel and Lodging: $7,194 · Food and Beverage: $1,360 · Honoraria: $1,200 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $57,842.87 |
| Travel and Lodging | $7,193.51 |
| Food and Beverage | $1,359.68 |
| Honoraria | $1,200.00 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19,757.89 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $12,611.44 | 2019-2024 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $10,768.57 | 2024-2025 | Imfinzi |
| Beone Medicines USA, INC. | $10,554.61 | 2025 | Tevimbra |
| Daiichi Sankyo INC. | $8,061.25 | 2021-2025 | |
| Gilead Sciences, INC. | $7,559.42 | 2025 | |
| Jazz Pharmaceuticals INC. | $3,120.00 | 2025 | |
| Beigene USA, INC. | $2,400.00 | 2025 | |
| Eisai INC. | $2,355.00 | 2023 | |
| Amgen INC. | $2,082.87 | 2024-2025 | |
| Coherus Oncology, INC. | $1,200.00 | 2024 | |
| Eusa Pharma (US) LLC | $225.00 | 2021 | |
| Array Biopharma INC | $138.67 | 2024 | |
| Astellas Pharma US INC | $124.03 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunnie Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.